Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

A role for 5-HT4 receptors in human learning and memory.

Murphy SE, Wright LC, Browning M, Cowen PJ, Harmer CJ.

Psychol Med. 2019 Oct 16:1-9. doi: 10.1017/S0033291719002836. [Epub ahead of print]

PMID:
31615585
2.

A Practical Approach to Establishing a Practice-Based Research Network Stakeholder Engagement Infrastructure.

Gaglioti AH, Walston D, Vasquez Guzman CE, Toppin Dera N, Ortiz C, Wright LC, Roberts T, Parker S, Young V.

J Am Board Fam Med. 2019 Sep-Oct;32(5):695-704. doi: 10.3122/jabfm.2019.05.190046.

3.

Effects of zamicastat treatment in a genetic model of salt-sensitive hypertension and heart failure.

Igreja B, Pires NM, Wright LC, Soares-da-Silva P.

Eur J Pharmacol. 2019 Jan 5;842:125-132. doi: 10.1016/j.ejphar.2018.10.030. Epub 2018 Oct 26.

PMID:
30401628
4.

OCT4 Acts as an Integrator of Pluripotency and Signal-Induced Differentiation.

Simandi Z, Horvath A, Wright LC, Cuaranta-Monroy I, De Luca I, Karolyi K, Sauer S, Deleuze JF, Gudas LJ, Cowley SM, Nagy L.

Mol Cell. 2016 Aug 18;63(4):647-661. doi: 10.1016/j.molcel.2016.06.039. Epub 2016 Aug 4.

5.

Insights into the activation mechanism of class I HDAC complexes by inositol phosphates.

Watson PJ, Millard CJ, Riley AM, Robertson NS, Wright LC, Godage HY, Cowley SM, Jamieson AG, Potter BV, Schwabe JW.

Nat Commun. 2016 Apr 25;7:11262. doi: 10.1038/ncomms11262.

6.

Sustained high blood pressure reduction with etamicastat, a peripheral selective dopamine β-hydroxylase inhibitor.

Igreja B, Wright LC, Soares-da-Silva P.

J Am Soc Hypertens. 2016 Mar;10(3):207-16. doi: 10.1016/j.jash.2015.12.011. Epub 2015 Dec 19.

PMID:
26803288
7.

Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action.

Soares-da-Silva P, Pires N, Bonifácio MJ, Loureiro AI, Palma N, Wright LC.

Pharmacol Res Perspect. 2015 Mar;3(2):e00124. doi: 10.1002/prp2.124. Epub 2015 Mar 30. Review.

8.

Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat.

Loureiro AI, Bonifácio MJ, Fernandes-Lopes C, Pires N, Igreja B, Wright LC, Soares-da-Silva P.

Xenobiotica. 2015;45(9):828-39. doi: 10.3109/00498254.2015.1018985. Epub 2015 Jun 10.

PMID:
25915108
9.

Blood pressure decrease in spontaneously hypertensive rats folowing renal denervation or dopamine β-hydroxylase inhibition with etamicastat.

Pires NM, Igreja B, Moura E, Wright LC, Serrão MP, Soares-da-Silva P.

Hypertens Res. 2015 Sep;38(9):605-12. doi: 10.1038/hr.2015.50. Epub 2015 Apr 9.

PMID:
25854989
10.

Characterization of the interaction of the novel antihypertensive etamicastat with human dopamine-β-hydroxylase: comparison with nepicastat.

Bonifácio MJ, Sousa F, Neves M, Palma N, Igreja B, Pires NM, Wright LC, Soares-da-Silva P.

Eur J Pharmacol. 2015 Mar 15;751:50-8. doi: 10.1016/j.ejphar.2015.01.034. Epub 2015 Jan 29.

PMID:
25641750
11.

Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus.

Sierra-Paredes G, Loureiro AI, Wright LC, Sierra-Marcuño G, Soares-da-Silva P.

BMC Neurosci. 2014 Dec 20;15:134. doi: 10.1186/s12868-014-0134-2.

12.

Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.

Bonifácio MJ, Torrão L, Loureiro AI, Palma PN, Wright LC, Soares-da-Silva P.

Br J Pharmacol. 2015 Apr;172(7):1739-52. doi: 10.1111/bph.13020. Epub 2015 Jan 20.

13.

Blood pressure-decreasing effect of etamicastat alone and in combination with antihypertensive drugs in the spontaneously hypertensive rat.

Igreja B, Pires NM, Bonifácio MJ, Loureiro AI, Fernandes-Lopes C, Wright LC, Soares-da-Silva P.

Hypertens Res. 2015 Jan;38(1):30-8. doi: 10.1038/hr.2014.143. Epub 2014 Oct 9.

PMID:
25298210
14.

The attention training technique, self-focused attention, and anxiety: a laboratory-based component study.

Fergus TA, Wheless NE, Wright LC.

Behav Res Ther. 2014 Oct;61:150-5. doi: 10.1016/j.brat.2014.08.007. Epub 2014 Aug 27.

PMID:
25213665
15.

Etamicastat, a new dopamine-ß-hydroxylase inhibitor, pharmacodynamics and metabolism in rat.

Loureiro AI, Bonifácio MJ, Fernandes-Lopes C, Igreja B, Wright LC, Soares-da-Silva P.

Eur J Pharmacol. 2014 Oct 5;740:285-94. doi: 10.1016/j.ejphar.2014.07.027. Epub 2014 Jul 21.

PMID:
25058908
16.

Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.

Rocha JF, Falcão A, Santos A, Pinto R, Lopes N, Nunes T, Wright LC, Vaz-da-Silva M, Soares-da-Silva P.

Eur J Clin Pharmacol. 2014 Sep;70(9):1059-71. doi: 10.1007/s00228-014-1701-2. Epub 2014 Jun 14.

PMID:
24925090
17.

Human disposition, metabolism and excretion of etamicastat, a reversible, peripherally selective dopamine β-hydroxylase inhibitor.

Loureiro AI, Rocha JF, Fernandes-Lopes C, Nunes T, Wright LC, Almeida L, Soares-da-Silva P.

Br J Clin Pharmacol. 2014 Jun;77(6):1017-26. doi: 10.1111/bcp.12274.

18.

Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.

Bonifácio MJ, Sutcliffe JS, Torrão L, Wright LC, Soares-da-Silva P.

Neuropharmacology. 2014 Feb;77:334-41. doi: 10.1016/j.neuropharm.2013.10.014. Epub 2013 Oct 19.

PMID:
24148813
19.

In silico comparison of genomic regions containing genes coding for enzymes and transcription factors for the phenylpropanoid pathway in Phaseolus vulgaris L. and Glycine max L. Merr.

Reinprecht Y, Yadegari Z, Perry GE, Siddiqua M, Wright LC, McClean PE, Pauls KP.

Front Plant Sci. 2013 Sep 5;4:317. doi: 10.3389/fpls.2013.00317. eCollection 2013.

20.

N-acetylation of etamicastat, a reversible dopamine-β-hydroxylase inhibitor.

Loureiro AI, Fernandes-Lopes C, Bonifácio MJ, Wright LC, Soares-da-Silva P.

Drug Metab Dispos. 2013 Dec;41(12):2081-6. doi: 10.1124/dmd.113.053736. Epub 2013 Sep 6.

PMID:
24013186
21.

Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects.

Rocha JF, Almeida L, Falcão A, Palma PN, Loureiro AI, Pinto R, Bonifácio MJ, Wright LC, Nunes T, Soares-da-Silva P.

Br J Clin Pharmacol. 2013 Nov;76(5):763-75. doi: 10.1111/bcp.12081.

22.

Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.

Almeida L, Rocha JF, Falcão A, Palma PN, Loureiro AI, Pinto R, Bonifácio MJ, Wright LC, Nunes T, Soares-da-Silva P.

Clin Pharmacokinet. 2013 Feb;52(2):139-51. doi: 10.1007/s40262-012-0024-7.

PMID:
23248072
23.

Population density and phenology of Tetranychus urticae (Acari: Tetranychidae) in hop is linked to the timing of sulfur applications.

Woods JL, Dreves AJ, Fisher GC, James DG, Wright LC, Gent DH.

Environ Entomol. 2012 Jun;41(3):621-35. doi: 10.1603/EN11279.

PMID:
22732621
24.

Characterization of seed coat post harvest darkening in common bean (Phaseolus vulgaris L.).

Elsadr HT, Wright LC, Pauls KP, Bett KE.

Theor Appl Genet. 2011 Dec;123(8):1467-72. doi: 10.1007/s00122-011-1683-8. Epub 2011 Aug 24.

PMID:
21863347
25.

Development and validation of an enantioselective liquid-chromatography/tandem mass spectrometry method for the separation and quantification of eslicarbazepine acetate, eslicarbazepine, R-licarbazepine and oxcarbazepine in human plasma.

Loureiro AI, Fernandes-Lopes C, Wright LC, Soares-da-Silva P.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Sep 1;879(25):2611-8. doi: 10.1016/j.jchromb.2011.07.019. Epub 2011 Jul 20.

PMID:
21816689
26.

Hepatic UDP-glucuronosyltransferase is responsible for eslicarbazepine glucuronidation.

Loureiro AI, Fernandes-Lopes C, Bonifácio MJ, Wright LC, Soares-da-Silva P.

Drug Metab Dispos. 2011 Sep;39(9):1486-94. doi: 10.1124/dmd.111.038620. Epub 2011 Jun 14.

PMID:
21673130
27.

Single-dose tolerability, pharmacokinetics, and pharmacodynamics of etamicastat (BIA 5-453), a new dopamine β-hydroxylase inhibitor, in healthy subjects.

Rocha JF, Vaz-Da-Silva M, Nunes T, Igreja B, Loureiro AI, Bonifácio MJ, Wright LC, Falcão A, Almeida L, Soares-Da-Silva P.

J Clin Pharmacol. 2012 Feb;52(2):156-70. doi: 10.1177/0091270010390805.

PMID:
21343348
28.

Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects.

Nunes T, Rocha JF, Vaz-da-Silva M, Igreja B, Wright LC, Falcão A, Almeida L, Soares-da-Silva P.

Drugs R D. 2010;10(4):225-42. doi: 10.2165/11586310-000000000-00000.

29.

Pharmacokinetics, disposition, and metabolism of [14C]-nebicapone in humans.

Wright LC, Maia J, Loureiro AI, Almeida L, Soares-Da-Silva P.

Drug Metab Lett. 2010 Aug;4(3):149-62.

PMID:
20642448
30.

Effects of powdery mildew fungicide programs on twospotted spider mite (Acari: Tetranychidae), hop aphid (Hemiptera: Aphididae), and their natural enemies in hop yards.

Gent DH, James DG, Wright LC, Brooks DJ, Barbour JD, Dreves AJ, Fisher GC, Walton VM.

J Econ Entomol. 2009 Feb;102(1):274-86.

PMID:
19253646
31.

Chitotriosidase and gene therapy for fungal infections.

Gordon-Thomson C, Kumari A, Tomkins L, Holford P, Djordjevic JT, Wright LC, Sorrell TC, Moore GP.

Cell Mol Life Sci. 2009 Mar;66(6):1116-25. doi: 10.1007/s00018-009-8765-7.

PMID:
19169854
32.

Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.

Ferreira JJ, Almeida L, Cunha L, Ticmeanu M, Rosa MM, Januário C, Mitu CE, Coelho M, Correia-Guedes L, Morgadinho A, Nunes T, Wright LC, Falcão A, Sampaio C, Soares-da-Silva P.

Clin Neuropharmacol. 2008 Jan-Feb;31(1):2-18. doi: 10.1097/wnf.0b013e3180645cb0.

PMID:
18303486
33.

Cell wall-linked cryptococcal phospholipase B1 is a source of secreted enzyme and a determinant of cell wall integrity.

Siafakas AR, Sorrell TC, Wright LC, Wilson C, Larsen M, Boadle R, Williamson PR, Djordjevic JT.

J Biol Chem. 2007 Dec 28;282(52):37508-14. Epub 2007 Oct 18.

34.

Role of conserved active site residues in catalysis by phospholipase B1 from Cryptococcus neoformans.

Jones PM, Turner KM, Djordjevic JT, Sorrell TC, Wright LC, George AM.

Biochemistry. 2007 Sep 4;46(35):10024-32. Epub 2007 Aug 9.

PMID:
17685590
35.

Synthesis, antifungal and antimicrobial activity of alkylphospholipids.

Obando D, Widmer F, Wright LC, Sorrell TC, Jolliffe KA.

Bioorg Med Chem. 2007 Aug 1;15(15):5158-65. Epub 2007 May 17.

PMID:
17532639
36.

Synthesis, antifungal and haemolytic activity of a series of bis(pyridinium)alkanes.

Ng CK, Singhal V, Widmer F, Wright LC, Sorrell TC, Jolliffe KA.

Bioorg Med Chem. 2007 May 15;15(10):3422-9. Epub 2007 Mar 13.

PMID:
17383187
37.

In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.

Tong Z, Widmer F, Sorrell TC, Guse Z, Jolliffe KA, Halliday C, Lee OC, Kong F, Wright LC, Chen SC.

Antimicrob Agents Chemother. 2007 Jun;51(6):2219-22. Epub 2007 Mar 19.

38.

Cryptococcal lipid metabolism: phospholipase B1 is implicated in transcellular metabolism of macrophage-derived lipids.

Wright LC, Santangelo RM, Ganendren R, Payne J, Djordjevic JT, Sorrell TC.

Eukaryot Cell. 2007 Jan;6(1):37-47. Epub 2006 Nov 10.

39.

N-linked glycosylation sites affect secretion of cryptococcal phospholipase B1, irrespective of glycosylphosphatidylinositol anchoring.

Turner KM, Wright LC, Sorrell TC, Djordjevic JT.

Biochim Biophys Acta. 2006 Oct;1760(10):1569-79. Epub 2006 Jul 13.

PMID:
16919392
40.

Human metabolism of nebicapone (BIA 3-202), a novel catechol-o-methyltransferase inhibitor: characterization of in vitro glucuronidation.

Loureiro AI, Bonifácio MJ, Fernandes-Lopes C, Almeida L, Wright LC, Soares-Da-Silva P.

Drug Metab Dispos. 2006 Nov;34(11):1856-62. Epub 2006 Jun 21.

PMID:
16790555
41.

Application of proton nuclear magnetic resonance spectroscopy to the study of Cryptococcus and cryptococcosis.

Sorrell TC, Wright LC, Malik R, Himmelreich U.

FEMS Yeast Res. 2006 Jun;6(4):558-66. Review.

42.
43.

Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis.

Widmer F, Wright LC, Obando D, Handke R, Ganendren R, Ellis DH, Sorrell TC.

Antimicrob Agents Chemother. 2006 Feb;50(2):414-21.

44.

Correlation of antifungal activity with fungal phospholipase inhibition using a series of bisquaternary ammonium salts.

Ng CK, Obando D, Widmer F, Wright LC, Sorrell TC, Jolliffe KA.

J Med Chem. 2006 Jan 26;49(2):811-6.

PMID:
16420066
45.
46.

Secretion of cryptococcal phospholipase B1 (PLB1) is regulated by a glycosylphosphatidylinositol (GPI) anchor.

Djordjevic JT, Del Poeta M, Sorrell TC, Turner KM, Wright LC.

Biochem J. 2005 Aug 1;389(Pt 3):803-12.

47.

Regulatory roles for the homeodomain and C2H2 zinc finger regions of Cryptococcus neoformans Ste12alphap.

Chang YC, Wright LC, Tscharke RL, Sorrell TC, Wilson CF, Kwon-Chung KJ.

Mol Microbiol. 2004 Sep;53(5):1385-96.

48.

Cryptococcal phospholipases: a novel lysophospholipase discovered in the pathogenic fungus Cryptococcus gattii.

Wright LC, Payne J, Santangelo RT, Simpanya MF, Chen SC, Widmer F, Sorrell TC.

Biochem J. 2004 Dec 1;384(Pt 2):377-84.

49.

Distribution patterns of entomopathogenic nematodes applied through drip irrigation systems.

Wennemann L, Cone WW, Wright LC, Perez J, Conant MM.

J Econ Entomol. 2003 Apr;96(2):287-91.

PMID:
14994792
50.

Cloning of CnLYSO1, a novel extracellular lysophospholipase of the pathogenic fungus Cryptococcus neoformans.

Coe JG, Wilson CF, Sorrell TC, Latouche NG, Wright LC.

Gene. 2003 Oct 16;316:67-78.

PMID:
14563553

Supplemental Content

Loading ...
Support Center